
Abeona Therapeutics ABEO
$ 4.77
-1.04%
Annual report 2025
added 03-17-2026
Abeona Therapeutics Long Term Debt Current 2011-2026 | ABEO
Annual Long Term Debt Current Abeona Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 864 K | 823 K | 998 K | 1.77 M | 1.82 M | 1.71 M | 1.7 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.82 M | 823 K | 1.38 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.12 | -0.36 % | $ 441 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
4.21 M | $ 8.32 | 3.67 % | $ 228 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 23.65 | 0.08 % | $ 3.01 B | ||
|
BioVie
BIVI
|
74.5 K | $ 1.46 | 2.82 % | $ 2.16 M | ||
|
BioLineRx Ltd.
BLRX
|
522 K | $ 2.32 | 4.98 % | $ 908 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 91.44 | 0.29 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
BioXcel Therapeutics
BTAI
|
65 K | $ 1.16 | -2.12 % | $ 14.2 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Cabaletta Bio
CABA
|
3.46 M | $ 3.1 | 4.56 % | $ 311 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.17 | 1.44 % | $ 6.9 B | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Catalyst Biosciences
CBIO
|
636 K | $ 19.48 | 0.39 % | $ 1.74 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
Codexis
CDXS
|
2.94 M | $ 1.95 | 6.87 % | $ 170 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Cerus Corporation
CERS
|
2.9 M | $ 1.91 | 2.69 % | $ 364 M | ||
|
Cullinan Management
CGEM
|
780 K | $ 15.11 | 4.71 % | $ 910 M | ||
|
Coherus BioSciences
CHRS
|
1.83 M | $ 1.72 | -0.87 % | $ 201 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
440 K | $ 0.46 | -13.02 % | $ 5.27 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
437 K | $ 24.95 | 1.05 % | $ 3.05 B | ||
|
Celldex Therapeutics
CLDX
|
1.55 M | $ 31.33 | 0.85 % | $ 2.08 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
1.63 M | $ 10.27 | 0.98 % | $ 137 M | ||
|
Cardiff Oncology
CRDF
|
730 K | $ 1.6 | 1.27 % | $ 107 M |